cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Erasca Inc
3 own
2 watching
Current Price
$1.79
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
255.77M
52-Week High
52-Week High
3.37500
52-Week Low
52-Week Low
1.51000
Average Volume
Average Volume
0.56M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization255.77M
icon52-Week High3.37500
icon52-Week Low1.51000
iconAverage Volume0.56M
iconDividend Yield--
iconP/E Ratio--
What does the Erasca Inc do?
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Read More
How much money does Erasca Inc make?
News & Events about Erasca Inc.
Globe Newswire
11 months ago
ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision ...
Ticker Report
1 year ago
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Alexander W. Casdin purchased 20,000 shares of the companys stock in a transaction dated Monday, April 10th. The shares were bought at an average cost of $2.76 per share, for a total transaction of $55,200.00. Following the acquisition, ...
Zolmax
1 year ago
Erasca, Inc. (NASDAQ:ERAS Get Rating) Director Alexander W. Casdin bought 20,000 shares of Erasca stock in a transaction dated Monday, April 10th. The stock was purchased at an average price of $2.76 per share, with a total value of $55,200.00. Following the purchase, the director now owns 463,974 ...
Globe Newswire
1 year ago
Shannon R. Morris, M.D., Ph.D., promoted to Chief Medical Officer Chandra D. Lovejoy promoted to Chief Regulatory Affairs Officer SAN DIEGO, April 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and ...
Globe Newswire
1 year ago
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim ...
Frequently Asked Questions
Frequently Asked Questions
What is Erasca Inc share price today?
plus_minus_icon
Can Indians buy Erasca Inc shares?
plus_minus_icon
How can I buy Erasca Inc shares from India?
plus_minus_icon
Can Fractional shares of Erasca Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Erasca Inc stocks?
plus_minus_icon
What is today’s traded volume of Erasca Inc?
plus_minus_icon
What is today’s market capitalisation of Erasca Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Erasca Inc?
plus_minus_icon
What percentage is Erasca Inc down from its 52-Week High?
plus_minus_icon
What percentage is Erasca Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.79
$0
(0%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00